Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8010092 | 0.86 | DPP4 (0.40) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL8576281 | 0.83 | DPP4 (0.39) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL498743 | 0.82 | ADORA3 (0.46) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL4738045 | 0.81 | DPP4 (0.50) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL8576286 | 0.80 | DPP4 (0.39) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL498576 | 0.80 | ADORA3 (0.44) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL8570077 | 0.79 | LTA4H (0.42) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL498705 | 0.79 | DPP4 (0.49) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL498431 | 0.76 | DPP4 (0.46) | DPP4LTA4HALDH1A1KDM4ENPC1 | |
| SCHEMBL8001586 | 0.76 | DPP4 (0.71) | DPP4LTA4HALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| EP-1357912-B1 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20120041356-A1 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE | QLT INC. (CA) | 2012-02-16 | — | — | US | disclosed |
| US-8106038-B2 | Method for reducing or preventing PDT related inflammation | QLT INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| EP-2379109-A1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | Qlt Inc. (CA) | 2011-10-26 | — | — | EP | disclosed |
| US-8034803-B2 | Treating an occult choroidal neovascular lesion | QLT INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062384-A2 | REDUCED FLUENCE RATE PDT | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062385-A2 | METHOD TO PREVENT VISION LOSS | QLT, INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085212-A2 | DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035997-A2 | USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | DPP4 2865/4885LTA4H 1099/4885ALDH1A1 371/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | DPP4 1489/4885LTA4H 846/4885ALDH1A1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.